Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to ease muscle weakness in rare nerve disease

NCT ID NCT06414954

Disease control Sponsor: NMD Pharma A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 3 times

Summary

This study tests an experimental pill called NMD670 in 84 adults with myasthenia gravis, a condition that causes muscle weakness. Participants take the pill or a placebo twice daily for 21 days. Researchers will measure changes in muscle strength and daily activities to see if the drug helps control symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NMD670 (tablet taken twice daily)
What this could lead to
If it works, this could point toward a new daily pill to help control muscle weakness in myasthenia gravis.
What could go wrong
This is an early Phase 2 trial with only 84 people over 21 days. It may not show clear benefit, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 84 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must be a male or female being 18 or more, at the time of signing the informed consent * Diagnosis of MG, MGFA class II, III or IV * Documented positive AChR or MuSK antibody test. * Participant must be able to swallow tablets * Body mass index between 18 and 35 kg/m2, inclusive, at screening, and with a minimum weight of 40 kg * Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies * Participant is capable of and has given signed informed consent Exclusion Criteria: * Known medical or psychological condition(s) or risk factor that, in the opinion of the Investigator, might interfere with the patient's full participation in the study, pose any additional risk for the patient, or confound the assessment of the patient or outcome of the study * Participants with other significant clinical and/or laboratory safety findings that may interfere with the conduction or interpretation of the study * Participants that received treatment with an investigational medical product within 30 days or 5 half-lives of the medication, whichever is longer prior to Day 1 * Participants with history of poor compliance with relevant MG therapy * Female patients who plan to become pregnant during the study or are currently pregnant or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myasthenia gravis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myasthenia gravis Myasthenia gravis, musk

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    33 sites in 8 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • AOU Pisana

    RECRUITING

    Pisa, 56126, Italy

  • ASST Papa Giovanni XXIII (Azienda Ospedaliera Papa Giovanni XXIII)

    RECRUITING

    Bergamo, 21127, Italy

  • Aarhus University Hospital

    RECRUITING

    Aarhus, Denmark

  • Augusta University, Neuroscience Center

    RECRUITING

    Augusta, Georgia, 30912, United States

  • Azienda Ospedaliera Sant'Andrea - Universita di Roma La Sapienza

    RECRUITING

    Roma, 00189, Italy

  • CHU de Nice

    RECRUITING

    Nice, France

  • Centre Hospitalier Universitaire de Nantes - Hôtel Dieu Centre de Référence des Maladies Neuromusculaires Rares -

    RECRUITING

    Nantes, France

  • Centre de Référence des Maladies Neuromusculaires et de la SLA

    RECRUITING

    Marseille, France

  • Centre de référence des maladies neuromusculaires AOC-CHU de Bordeaux - Hôpital Pellegrin

    RECRUITING

    Bordeaux, France

  • Centro Sclerosi Multipla Napoli - AOU Vanvitelli

    RECRUITING

    Naples, 80138, Italy

  • Centrum Medyczne Hope Clinic

    RECRUITING

    Lublin, 20701, Poland

  • Centrum Medyczne Neuro Protect

    RECRUITING

    Warsaw, Poland

  • DIMER, IRCCS, Ospedale San Raffaele

    RECRUITING

    Milan, Italy

  • Galen Clinic

    RECRUITING

    Lublin, Poland

  • Hospìtal Universitari Vall d'Hebrón

    RECRUITING

    Barcelona, Spain

  • IRCCS Fondazione Istituto Neurologico Carlo Besta, Dipartimento di Ricerca e Sviluppo clinico

    RECRUITING

    Milan, 20133, Italy

  • IRCCS Istituo delle Scienze neurologiche di Bologna, UOC Clinica neurologica Ospedale

    RECRUITING

    Bologna, 40139, Italy

  • IRCCS Ospedale Policlinico San Martino

    RECRUITING

    Genova, 16132, Italy

  • JSC Curatio

    ACTIVE_NOT_RECRUITING

    Tbilisi, Georgia

  • LTD David Tatishvili Health Center

    ACTIVE_NOT_RECRUITING

    Tbilisi, Georgia

  • Leiden Universitair Medisch Centrum (LUMC)

    RECRUITING

    Leiden, 2333, Netherlands

  • Ltd New Hospitals

    ACTIVE_NOT_RECRUITING

    Tbilisi, Georgia

  • NeuroCor Banaszkiewicz, Tomaszewski Lekarze Spółka Partnerska

    RECRUITING

    Myślenice, Poland

  • Neurologia Śląska Centrum Medyczne

    RECRUITING

    Katowice, Poland

  • Neuromuscular Research Division | University of South Florida

    RECRUITING

    Tampa, Florida, 33612, United States

  • NextGen Precision Health

    RECRUITING

    Columbia, Missouri, 65212, United States

  • Profound Research LLC

    WITHDRAWN

    Carlsbad, California, 92011, United States

  • Rigshospitalet University of Copenhagen

    RECRUITING

    Copenhagen, Denmark

  • SFM Clinical Research, LLC

    RECRUITING

    Boca Raton, Florida, 33487, United States

  • Semmes Murphey Clinic

    WITHDRAWN

    Memphis, Tennessee, 38120, United States

  • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie sp.z o.o

    RECRUITING

    Krakow, Poland

  • The Ohio State University

    RECRUITING

    Columbus, Ohio, 43221, United States

  • The University of North Carolina at Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

  • UZ Leuven

    WITHDRAWN

    Leuven, Belgium

  • Unité de Recherche Clinique NeuroSciences

    RECRUITING

    Nice, France

  • University Clinical Center Nis, Neurology Clinic

    RECRUITING

    Niš, Serbia

  • University Clinical Center of Serbia, Neurology Clinic

    WITHDRAWN

    Belgrade, Serbia

  • University of California Irvine Medical Center

    RECRUITING

    Irvine, California, 92868, United States

  • University of Colorado Neuromuscular Division

    RECRUITING

    Aurora, Colorado, 80045, United States

    Contact Email: •••••@•••••

  • University of Oregon

    RECRUITING

    Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.